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Abstract
Background: We investigated the association between trajectories of verbal episodic memory and burden of
cardiovascular risk factors in middle-aged and older community-dwellers.
Methods: We analysed data from 4372 participants aged 50–64 and 3005 persons aged 65–79 years old from the
English Longitudinal Study of Ageing who were repeatedly evaluated every 2 years and had six interviews of a 10-
year follow-up. We measured the following baseline risk factors: diabetes, hypertension, smoking, physical inactivity
and obesity to derive a cardiovascular risk factor score (CVRFs). Adjusted linear mixed effect regression models were
estimated to determine the association between number of CVFRs and six repeated measurements of verbal
memory scores, separately for middle-aged and older adults.
Results: CVRFs was not significantly associated with memory at baseline. CVFRs was significantly associated with
memory decline in middle-aged (50-64y), but not in older (65-79y) participants. This association followed a dose-
response pattern with increasing number of CVFRs being associated with greater cognitive decline. Comparisons
between none versus some CVRFs yielded significant differences (p < 0.05).
Conclusions: Our findings confirm that the effect of cumulative CVRFs on subsequent cognitive deterioration is
age-dependent. CVRFs are associated with cognitive decline in people aged 50–64 years, but not in those aged
≥65 years. Although modest, the memory decline associated with accumulation of cardiovascular risk factors in
midlife may increase the risk of late-life dementia.
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Background
Cardiovascular risk factors (CVRFs) (tobacco smoking,
hypertension, obesity, physical inactivity and diabetes)
are highly prevalent among midlife and older adults [1],
and constitute leading causes of mortality. Of the 2.5
million Americans who died in 2005, tobacco smoking
killed 1 in 5, elevated blood pressure was responsible for
1 in 6 deaths, and obesity and physical inactivity took 1
in 10 lives [2]. Besides this augmented risk for death,
population-based studies have also identified CVRFs as
strongly related to higher risk for accelerated cognitive
decline [3, 4] and dementia [5]. For example, current
smokers are between 50 and 80% more likely to develop
Alzheimer’s Disease (AD) in the future, compared with
those who never smoked [6, 7], and older adults who en-
gage in high leisure-time physical activity have approxi-
mately 45% less risk of AD than people with the lowest
level [8]. The effect of CVRFs on cognitive deterioration
is mostly, but not exclusively, driven by cardiovascular
diseases (CVD) [9]. Other pathophysiological mecha-
nisms through which CVRFs might impact on cognitive
decline or risk for dementia include inflammation and
oxidative stress, cerebral small vessel diseases, cerebral
hypoxia and hypoperfusion, or neurodegeneration in the
brain, which in turn might also increase the risk for
heart disease [10]. Several epidemiological studies have
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shown that the effect of several CVRFs on cognitive de-
terioration follows a dose-response pattern [10]. Thus,
composite scores of CVRFs are often used as potential
tools to detect at-risk older adults for cognitive decline
and dementia.
Despite the association between CVRFs in older adults
and risk for dementia being well-established [5, 9, 11], sev-
eral authors postulate that this relationship might be age-
dependent [12]. High blood pressure during midlife has
been shown to be associated with an increased risk of AD
in late life [13, 14], whereas research on the effect of high
blood pressure in late life and dementia has yielded mixed
results [9]. Similarly, the association of obesity and AD
seems to be also age-dependent, with obesity in midlife re-
ported as risk factor for AD [15], and underweight in late-
life being more important in predicting AD [16]. Other
studies have also demonstrated that aggregated CVRFs at
midlife are associated with cognitive decline in the middle
age [17, 18], suggesting that this effect can be observed at
early stages. The associations between CVRFs during late
life and dementia are less clear, with several studies
finding very small or null effects on subsequent cognitive
deterioration [13, 19].
Comparison across these studies focusing on middle-
age versus late-life might be challenging because of
distinct study designs, measures and sampling character-
istics. To the authors’ knowledge, no studies have com-
pared the impact of a summary score of CVRFs on
subsequent cognitive deterioration in population-based
middle aged versus older cohorts. The impact of a sum-
mary score of CVRFs at baseline on subsequent trajec-
tories of cognition (verbal episodic memory) over a
period of 10 years was investigated in a longitudinal,
nationally-representative cohort of adults aged 50 to 64
and 65 to 79 years old. We aimed to study whether this
association followed a dose-response pattern by explor-
ing the interaction between time and CVRFs. Models
were adjusted for several confounders to determine
whether this association was above and beyond the effect
of potential explanatory variables. The stratification of
models by two age cohorts (middle-aged and older
adults) allowed us explore age differences in the asso-
ciation between CVRFs and cognitive decline.
Methods
Study population
This study analysed data from the English Longitudinal
Study of Ageing (ELSA), an ongoing project intended
to collect data to study the dynamics of health, social,
wellbeing and economic circumstances in the English
population aged 50+, and more details about the study
can be found elsewhere [20]. Briefly, it is a longitudinal,
nationally representative survey of people aged 50 years
and older living in private addresses in England. It was
a randomized, stratified, multi-stage sample of partici-
pants [20] who earlier had taken part of the Health
Survey England (1998, 1999 and 2001). The baseline
sample (11,391 core members) was first assessed in
2002–03 and re-assessed every 2 years. Data are freely
available from the UK Data Archive (https://beta.ukda-
taservice.ac.uk).
The present study used data from 6 successive waves
of ELSA over 10 years of follow-up. We focused on
core members who completed a non-proxy interview
at baseline (n = 11,233) and excluded those who were
aged 80+ at baseline (n = 10,026). Eighty-two partici-
pants who reported at baseline to have been diagnosed
by a doctor with AD, Parkinson’s disease, dementia,
organic brain syndrome, senility or any other serious
memory impairment were excluded. Participants with
information on verbal episodic memory score at base-
line and at least in another wave and with complete
information in all covariates (age, gender, educational
and wealth level, marital status, number of CVD and
non-CVD diseases) were included in the analysis,
resulting in a final n of 7377.
Measures
Outcomes
The ELSA study includes a battery of cognitive tests to
measure cognitive functioning in the elderly [21]. We fo-
cused on verbal episodic memory, which is related to
every-day activities of older adults and has been shown to
be sensitive to age-related decline [22]. The measure was
assessed in the six waves using both immediate and de-
layed word recall tasks in which ten common words were
presented aurally by computer to ensure standardised de-
livery. Participants were asked to recall them immediately
and after a short delay, which was filled with other cogni-
tive tests. There were four alternative lists, so that different
lists could be given in distinct waves. The number of cor-
rect responses was recorded each time. This approach has
been used elsewhere [21], and the word lists used here
were those developed for the Health Retirement Study
(HRS) [23]. The number of recalled words from both tests
was added to obtain a total memory score (ranging from 0
to 20) with higher scores indicating better memory. The
correlation coefficients between the immediate and de-
layed recall at baseline was 0.65. Immediate and delayed
recalls have been known to have good construct validity
and consistency [24].
Cardiovascular risk factor score Following the litera-
ture [11], we generated a summary score, which in-
cluded the following baseline CVRFs: self-reported
hypertension and diabetes, history of smoking (current
or ever vs. never), objectively measured obesity (Body
Mass Index (BMI) > 30 kg/m2) and physical inactivity
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(not at all or mild physical activity vs. moderate or vigor-
ous physical activity at least once a week). As BMI was
not measured at baseline in 2002–03, we used BMI data
that were measured in the Health Survey for England in
1998, 1999 and 2001. The CVRFs score initially ranged
from 0 to 5. Due to the small number of people with 4
and 5 CVRFs, these categories were collapsed, and finally
the CVRFs score had four categories, ranging from 0 to
≥3 CVRFs.
Covariates Covariates were measured at baseline and
included sex, age, marital status (never married, legally
separated or divorced, married/remarried, and
widowed), education (A-level or above recorded as
high; O-level/Secondary education recorded as medium
level; and no qualifications recorded as low education),
quintiles of total net non-pension household wealth
(including the net worth of savings and investments,
property and business assets, but not pension-related
assets), number of self-reported CVDs (angina, heart
attack, congestive heart, abnormal heart rhythm, and
stroke) and non-CVDs (chronic lung diseases, asthma,
arthritis, osteoporosis, and cancer). Summary scores of
CVDs and non-CVDs were generated. Depressive
symptoms were assessed using the short 8-item Centre
for Epidemiologic Studies Depression Scale (CES-D)
[25]. We calculated a summary CES-D score using all
eight binary (Yes/No) symptom items. The CES-D
summary score ranged from 0 to 8, with higher scores
indicating more depressive symptoms.
Statistical analysis
Unadjusted and adjusted linear mixed effect regression
models were estimated separately for the middle-aged
(50–64 years) and older cohorts (65–79 years). The ad-
justed models included the covariates aforementioned.
Time as continuous variable (from 0 to 10 years) was
included in the models. To account for non-response,
including survivor bias [26], we adjusted our models for
a variable distinguishing between completers (partici-
pants who had complete memory data in all visits) and
drop-outs (participants who missed at least one wave of
ELSA for any reason including intermittent attrition,
death and drop-out). To explore whether the rate of
memory decline was different across the number of
CVRFs, the interaction CVRFs*time was included in the
adjusted models. Intercepts and slopes were measured as
random effects. Since CVRFs are highly correlated with
the presence of CVDs, adjustment for CVDs may atte-
nuate the association of CVRFs with cognition. Thus, we
also calculated the adjusted models excluding this
variable (see Additional file 1: Table S1).
Marginal effects were used to graph linear adjusted
predictions of verbal episodic memory over the follow-
up while holding covariates constant. Post-hoc correc-
tions (Bonferroni) for multiple comparisons were
performed.
Analyses were conducted with SAS 9.4 (SAS Institute,
Cary NC) using the PROC MIXED procedure and Stata
(SE version 13, College Station, TX). A two-side p value of
less than 0.05 was considered as statistically significant.
Results
Table 1 presents a descriptive analysis of the total sam-
ple (N = 7377) and by age cohorts.
Compared with the younger cohort, older participants
presented higher rates of low education level (p < 0.001),
and higher proportions of two or more non-CVDs and
CVDs (p < 0.001). The prevalence of number of CVRFs
was also higher in the older cohort (p < 0.0001). Mean
score of episodic memory at baseline was lower than
middle-aged people (p < 0.001). Number of depressive
symptoms was also higher (p < 0.01). Some 22.5% of
older participants died by the end of the study, and
45.6% completed all the assessments.
Trajectories of verbal memory score
Table 2 shows parameters from unadjusted and adjusted
models in both samples. In the unadjusted models, there
was a significant dose-response cross-sectional associ-
ation between number of CVRFs and baseline memory
function in both middle-aged and older adults, with
higher number associated with lower memory scores
(p < 0.0001). Longitudinally, there was a significant im-
provement in memory scores over time in middle-aged
participants (p < 0.05), whereas a decline was observed in
older participants (p < 0.0001).
After adjusting for covariates, in middle-aged partici-
pants, the cross-sectional association between CVRFs at
baseline and memory score was no longer significant
(p = 0.079). Participants who did not miss a study wave
had better memory scores than those who missed at
least one study wave (p < 0.001). Compared with the
lowest quintile of wealth, higher levels of wealth were as-
sociated with better memory. Females, compared with
males, and persons with higher levels of education had
significantly better levels of memory (p < 0.001).
Regarding longitudinal changes in middle-aged
persons, the interaction CVRFs*wave was significant
(p = 0.004) indicating that different categories of CVRFs
presented distinct patterns of decline over time.
For people aged 65–79 years, verbal episodic memory
was still affected by time after adjustment, with a decline
of 0.10 points every 2 years (p < 0.001), whereas the
CVRFs were not associated with memory neither cross-
sectionally not longitudinally; the interaction term be-
tween CVRFs and time were not statistically significant
(overall significance p < 0.478).
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Table 1 Descriptive characteristics of the overall sample (N = 7377) and by age groups
Age group
Overall sample 50–64 65–79 P value
N = 7377 n = 4372 (59.3%) n = 3005 (40.7%)
Socio-demographics characteristics
Female, n (%) 3996 (54.2%) 2349 (53.7%) 1647 (54.8%) .360
Age, mean (SD) 62.6 (8.1) 56.8 (4.1) 71 (4.1) <.001
Marital status, n (%)
Never married 380 (5.2%) 244 (5.6%) 136 (4.5%) <.001
Married/remarried 5190 (70.4%) 3257 (74.5%) 1933 (64.3%)
Separated/divorced 870 (11.8%) 632 (14.5%) 238 (7.9%)
Widowed 937 (12.7%) 239 (5.5%) 698 (23.2%)
Education level, n (%) <.001
Low 2785 (37.8%) 1304 (29.8%) 1481 (49.3%)
Medium 2269 (30.8%) 1408 (32.2%) 861 (28.7%)
High 2323 (31.5%) 1660 (38.0%) 663 (22.1%)
Quintiles of wealth, n (%) <.001
Lowest 1163 (15.8%) 596 (13.6%) 567 (18.9%)
2nd 1405 (19.1%) 808 (18.5%) 597 (19.9%)
3rd 1516 (20.6%) 904 (20.7%) 612 (20.4%)
4th 1625 (22%) 992 (22.7%) 633 (21.1%)
Highest 1668 (22.6%) 1072 (24.5%) 596 (19.8%)
Cardiovascular risk factors
High blood pressure, n (%) 2671 (36.2%) 1340 (30.6%) 1331 (44.3%) <.001
Diabetes, n (%) 476 (6.5%) 205 (4.7%) 271 (9.0%) <.001
Obesity, n (%) 1914 (26%) 1128 (25.8%) 786 (26.2%) .732
Currently or past smoking, n (%) 4711 (63.9%) 2784 (63.7%) 1927 (64.1%) .694
Physical inactivity, n (%) 1427 (19.3%) 714 (16.3%) 713 (23.7%) <.001
Number of cardiovascular risk factors, n (%) <.001
None 1172 (15.9%) 785 (18.0%) 387 (12.9%)
One 2876 (39%) 1810 (41.4%) 1066 (35.5%)
Two 2014 (27.3%) 1130 (25.8%) 884 (29.4%)
Three or more 1315 (17.8%) 647 (14.8%) 668 (22.2%)
Non-CVDs
Chronic lung disease, n (%) 440 (6%) 214 (4.9%) 226 (7.5%) <.001
Asthma, n (%) 852 (11.6%) 519 (11.9%) 333 (11.1%) 0.297
Arthritis, n (%) 2241 (30.4%) 1129 (25.8%) 1112 (37.0%) <.001
Osteoporosis, n (%) 327 (4.4%) 132 (3.0%) 195 (6.5%) <.001
Cancer, n (%) 413 (5.6%) 204 (4.7%) 209 (7.0%) <.001
Number of non-CVDs, n (%) <.001
None 4081 (55.3%) 2655 (60.7%) 1426 (47.5%)
One 2484 (33.7%) 1319 (30.2%) 1165 (38.8%)
Two or more 812 (11%) 398 (9.1%) 414 (13.8%)
CVDs
Angina, n (%) 629 (8.5%) 232 (5.3%) 397 (13.2%) <.001
Heart attack, n (%) 379 (5.1%) 138 (3.2%) 241 (8.0%) <.001
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The exclusion of CVDs from the adjusted models
yielded similar results, as can be seen in Additional
file 1: Table S1.
Figure 1 shows the trajectories of predicted means of
verbal episodic memory over time for each number of
CVRFs, stratified by age cohorts and adjusted for covar-
iates. For middle-aged participants (Fig. 1a), those with-
out CVRFs showed a significant improvement in
memory scores over time, with a positive slope (b =
0.040, SE = 0.012, p < 0.01). By contrast, this improve-
ment was not observed in those with one (b = 0.005,
SE = 0.008, p = 0.55), two (b = − 0.005, SE = 0.01, p =
0.581) or three or more CVRFs (b = − 0.021, SE = 0.014,
p = 0.125). Differences between the slopes of one, two
and three or more, compared with none CVRFs, were all
significant (p < 0.05 after Bonferroni correction). There
were no significant differences when comparing slopes
across one, two and three or more CVRFs.
Figure 1b shows adjusted trajectories of verbal epi-
sodic memory for older adults (i.e., aged 65 to 79).
Again, slopes for each CVRF were estimated using mar-
ginal effects from the adjusted model in Table 2. Older
adults with none CVRFs presented a significant decline
over time (b = − 0.096, SE = 0.019, p < 0.001). A
significant decline was also observed in those with one
(b = − 0.131, SE = 0.012, p < 0.001), two (b = − 0.127,
SE = 0.014, p < 0.001) and three or more CVRFs (b=− 0.123,
SE = 0.016, p < 0.001). However, comparisons between
these slopes yielded non-significant differences.
Discussion
Overall, our findings suggest a greater cardiovascular
risk burden on contemporaneous memory decline in
midlife, but not in late-life, supporting the hypothesis
that the deleterious effect of cumulative CVRFs is age-
dependent [10]. They also suggest that the effect of
CVRFs follows a dose-response association with verbal
episodic memory decline which is independent of other
potential confounders.
As has been previously suggested, the presence of
CVRFs in midlife is related to increased risk for late-
onset cognitive impairment and dementia [27, 28].
Anstey et al. [17] speculated that, if these risk factors for
late-life dementia occur in midlife, some effects on cog-
nitive functioning, despite small, might be detectable in
middle age. These authors found that greater CVRF bur-
den, measured with a composite score of several risk fac-
tors, was associated with faster decline in reaction time.
Similarly, other previous longitudinal population-based
studies found worse cognitive performance associated
with CVRFs in midlife [4, 18, 29]. In our study, middle-
aged participants with no CVRFs show an improvement
in their memory performance over 10 years. This lack of
cognitive deterioration over time, or even some im-
provement due to practice effect, has been documented
in previous research based on general populations, espe-
cially among younger and middle-aged adults [17, 30].
However, our results show that participants aged 50 to
64 years who had one, two or three or more CVRFs did
Table 1 Descriptive characteristics of the overall sample (N = 7377) and by age groups (Continued)
Age group
Congestive heart failure, n (%) 48 (0.7%) 13 (0.3%) 35 (1.2%) <.001
Abnormal heart rhythm, n (%) 431 (5.8%) 204 (4.7%) 227 (7.6%) <.001
Stroke, n (%) 217 (2.9%) 74 (1.7%) 143 (4.8%) <.001
Number of CVDs, n (%) <.001
None 6103 (82.7%) 3868 (88.5%) 2235 (74.4%)
One 945 (12.8%) 392 (9.0%) 553 (18.4%)
Two or more 329 (4.5%) 112 (2.6%) 217 (7.2%)
Missing-data pattern
Completer, n (%) 3924 (53.2%) 2553 (58.4%) 1371 (45.6%) <.001
Non-completer, n (%) 3453 (46.8%) 1819 (41.6%) 1634 (54.4%)
Depression
CES-D, mean (SD) 1.5 (1.9) 1.4 (2) 1.5 (1.9) .005
Outcome
Immediate recall, mean (SD) 5.70 (1.63) 6.06 (1.55) 5.18 (1.61) <.001
Delayed recall, mean (SD) 4.28 (1.99) 4.74 (1.86) 3.61 (1.98) <.001
Total score episodic memory, mean (SD) 10.0 (3.3) 10.8 (3.1) 8.8 (3.3) <.001
Note: SD Standard Deviation, CES-D Center for Epidemiologic Studies Depression Scale, non CVDs non-cardiovascular diseases, CVDs Cardiovascular diseases. CES-D
scores ranged from 0 to 8; immediate and delayed recall ranged from 0 to 10; total score for episodic memory ranged from 0 to 20; low education level included
people with no qualifications
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Table 2 Parameter estimates, Standard Errors and p values from adjusted linear mixed regression models for episodic memory
scores
Unadjusted models Adjusted models
Parameter Categories Middle-aged Older adults Middle-aged Older people
Estimation SE p Estimation SE p Estimation SE p Estimation SE p
Intercept 8.384 0.220 <.0001 6.60 0.311 <.0001
Time (per year) 0.010 0.005 .039 −0.115 0.007 <.0001 0.040 0.011 .001 −0.096 0.019 <.0001
CVRFs None Ref. Ref. Ref. Ref.
One −0.470 0.105 <.0001 −0.376 0.161 .020 − 0.056 0.106 0.599 0.139 0.157 0.378
Two −1.101 0.115 <.0001 −0.792 0.166 <.0001 − 0.245 0.118 0.038 0.111 0.164 0.498
Three or more −1.463 0.131 <.0001 −1.414 0.174 <.0001 −0.241 0.137 0.080 −0.194 0.175 0.268
Age (centred) −0.132 0.009 <.0001 −0.197 0.012 <.0001 −0.110 0.008 <.0001 −0.153 0.011 <.0001
CES-D −0.248 0.019 <.0001 −0.246 0.027 <.0001 −0.149 0.018 <.0001 −0.119 0.025 <.0001
Missing-data
pattern
Non-completers Ref. Ref. Ref. Ref.
Completers 0.961 0.077 <.0001 1.602 0.097 <.0001 0.550 0.069 <.0001 1.090 0.091 <.0001
Wealth 1-quintile (lowest) Ref. Ref. Ref. Ref.
2-quintile 0.641 0.076 <.0001 0.849 0.156 <.0001 0.221 0.121 .068 0.515 0.143 <.0001
3-quintile 1.265 0.128 <.0001 1.340 0.155 <.0001 0.532 0.123 <.0001 0.780 0.146 <.0001
4-quintile 1.761 0.126 <.0001 1.728 0.153 <.0001 0.746 0.124 <.0001 0.875 0.150 <.0001
5-quintile (highest) 2.105 0.124 <.0001 2.476 0.155 <.0001 0.973 0.128 <.0001 1.371 0.159 <.0001
Gender Males Ref. Ref. Ref. Ref.
Female 0.668 0.076 <.0001 0.612 0.101 <.0001 0.863 0.069 <.0001 0.855 0.094 <.0001
Education level Low Ref. Ref. Ref. Ref.
Medium 1.470 0.090 <.0001 1.375 0.113 <.0001 1.034 0.087 <.0001 0.964 0.106 <.0001
High 2.267 0.087 <.0001 2.055 0.122 <.0001 1.711 0.090 <.0001 1.443 0.122 <.0001
Marital status Never married Ref. Ref. Ref. Ref.
Married/remarried 0.555 0.167 .001 0.885 0.245 <.0001 0.255 0.146 .082 0.353 0.214 .099
Legally separated or
divorced
0.262 0.190 0.167 0.733 0.297 0.014 0.295 0.166 .075 0.434 0.258 .092
Widowed 0.013 0.229 0.954 0.524 0.259 0.043 0.202 0.202 .316 0.560 0.226 .013
Non-CVDs None Ref. Ref. Ref. Ref.
One −0.250 0.085 .003 0.017 0.109 0.875 0.050 0.075 .506 0.156 0.096 .106
Two or more −0.546 0.135 <.0001 −0.072 0.155 0.641 0.122 0.123 .322 0.348 0.139 .013
CVDs None Ref. Ref. Ref. Ref.
One −0.668 0.133 <.0001 −0.363 0.131 <.001 −0.157 0.118 .181 −0.017 0.115 .883
Two or more −1.289 0.241 <.0001 −0.753 0.198 <.0001 −0.154 0.216 .478 −0.068 0.175 .695
CVRFs*time None*time Ref. Ref.
One*time (per yr) −0.035 0.014 .013 −0.035 0.022 .122
Two*time (per yr) −0.45 0.015 .003 −0.030 0.023 .197
Three or more*time
(per yr)
−0.061 0.018 .001 −0.027 0.025 .286
Random variance
Intercept 3.438 0.186 <.0001 4.101 0.263 <.0001
Linear slope 0.062 0.010 <.001 0.122 0.016 <.0001
Residual 4.968 0.060 <.001 5.313 0.082 <.0001
Note: In bold, significant effect
SE Standard error, CVRFs Cardiovascular risk factors score, CES-D Centre for Epidemiologic Studies Depression Scale, CVDs Cardiovascular diseases, non-
CVDs non cardiovascular diseases
CES-D scores ranged from 0 to 8; Episodic memory scores ranged from 0 to 20; low education level included people with no qualifications
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not experience this improvement and did significantly
worse compared with those free of CVRFs. Albeit subtle,
the observed effect of CVRFs on verbal episodic memory
is potentially important and meaningful, since one would
expect memory not to deteriorate to an observable
extent in middle-aged adults [31, 32].
Our findings also indicate that prospective association
between cumulative CVRFs and memory in participants
aged 50–64 years is dose-response with the memory
score getting lower for every additional CVRF. The
existing evidence concurs with that and suggests that
composites of CVRFs have been shown to have a dose-
dependent effect on the risk for dementia [33]. Since
these risk factors frequently co-exist, intervention fo-
cusing on the combined effect of multiple CVRFs is
preferable rather than focusing only on individual risk
factors [3].
As for older adults (i.e., aged 65 to 79), we found that
there were a significant decline of memory over time,
but this was not associated with the number of baseline
CVRFs. Previous literature has yielded mixed results
when analysing the effect of summary risk scores of
CVRFs in later life on risk of dementia, with some
population-based studies reporting a positive effect [34,
35], and others failing to report significant effects of
CVRFs in late-life on subsequent deterioration of
Fig. 1 Trajectories of predicted mean for verbal episodic memory in middle-aged and older participants Note: Predicted means were calculated
from adjusted linear mixed models (see Table 2) while covariates were held constant. CVRFs = cardiovascular risk factors. a Middle aged
participants, 50–64 years old (n = 4372). b Older participants, 65–79 years old (n = 3005)
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cognitive function [5]. It has been also suggested that
CVRFs no longer act as risk factors for dementia [10].
For example, obesity during midlife has been demon-
strated to be a risk factor for late-life dementia, whereas
for older ages, being underweighted is related to in-
creased risk for cognitive impairment [12]. This U-
shaped relationship has been similarly found for hyper-
tension [36]. Higher levels of blood pressure at midlife
which decrease over time has been shown to be associ-
ated with increased white matter lesions [37]. In a previ-
ous study conducted on the ELSA survey [38], we
similarly found that the number of CVDs was only sig-
nificantly related to subsequent latent trajectories of ver-
bal episodic memory in midlife but not in late-life. A
recent investigation with the ELSA study also reported
that the co-occurrence of diabetes type II and elevated
depressive symptoms was associated with accelerated
cognitive decline, especially among those aged 50–64
years [39]. Therefore, it is possible that cognitive deteri-
oration in older adults is being affected by different
pathways or risk factors. Overall, middle-aged partici-
pants present with better levels of health at baseline than
older participants. The number of non-CVDs and CVDs
were significantly higher in the older cohort, and this
might have greatly impact on their memory function.
For example, musculoskeletal disease, lung disease or
arthritis have been previously linked to cognitive decline
[40]. Despite the fact that we controlled for the presence
of multimorbidity (including both CVDs and non-
CVDs), it is possible that the effect of chronic conditions
on participants’ memory function might be more salient
on the older cohort than in midlife, thus attenuating the
detrimental effect of CVRFs in older participants. There
is also the hypothesis that the duration of the exposure
to CVRFs might impact on the rate of cognitive decline.
Some previous research has supported this when study-
ing diabetes in middle-aged adults [41, 42], hypertension
[43], or smoking [44]. Future studies to investigate how
age of onset of these CVRFs is impacting on cognitive
functioning are warranted.
Survival bias might also partially explain this lack of
differences. Presence of CVRFs in younger ages or mid-
life are related to higher risk for death [45], and thus
older participants in our study might be healthier than
expected. Cohort effects can also explain this lack of sig-
nificance. Older and younger cohorts might be exposed
to different risk factors or historical events during their
lifespan [46].
Some limitations should be considered when interpret-
ing our findings. First, some CVRFs at baseline were
self-reported and they could have been affected by recall
bias or low accuracy, especially for the older cohort [47].
Second, the age of onset for CVRFs was not considered
in this study despite the fact that the duration of these
conditions might play an important role on subsequent
memory decline. Third, we focused on verbal episodic
memory. CVRFs might affect differently the trajectories
of other cognitive domains (e.g., attention, verbal
fluency). Moreover, one could not discard floor effect,
especially in the older age group. Fourth, despite the fact
that we excluded those individuals who self-reported
being diagnosed with dementia or other brain disorders,
it is possible that some others might have presented with
milder forms of neurodegenerative disorders, such as
mild cognitive impairment (MCI). This would be par-
ticularly important if the presence of MCI is contribu-
ting to lower baseline cognitive scores and muting the
test-retest effect at follow-up, especially in the older
group. Finally, non-response might have also introduced
some bias. However, we controlled for the confounding
effect of completion.
Conclusions
Our findings support the deleterious effect of aggregate
CVRFs in midlife (50–64 years) on subsequent decline
over a period of 10 years, whereas this association was
not found when CVRFs were measured in older adults
(over 65 years). Despite being subtle, the decline obser-
ver among middle-aged adults with a high cardiovascular
burden was significantly different from that observed for
people with no CVRFs, where an improvement was
observed. These differences in cognitive decline might
increase as people aged, leading to greater risk for future
dementia, such as AD. Interventions over these modifi-
able conditions at midlife could help stop this cognitive
deterioration.
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